Allogene Therapeutics
ALLO
176 hedge funds and large institutions have $582M invested in Allogene Therapeutics in 2023 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 62 increasing their positions, 48 reducing their positions, and 21 closing their positions.
43% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 21
29% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 48
5.91% more ownership
Funds ownership: 75.65% → 81.57% (+5.9%)
5% more funds holding
Funds holding: 167 → 176 (+9)
15% less capital invested
Capital invested by funds: $686M → $582M (-$104M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
84% less call options, than puts
Call options by funds: $333K | Put options by funds: $2.13M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$24.4M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$10.1M |
| 3 |
JP Morgan Chase
New York
|
+$8.04M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$7.05M |
| 5 |
Primecap Management
Pasadena,
California
|
+$5.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$14.6M |
| 2 |
State Street
Boston,
Massachusetts
|
-$6.13M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$4.68M |
| 4 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$3.92M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$3.1M |
ALLO Hedge Fund Activity: Q1 2023 in Review
176 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q1 2023, worth a combined $582M — down 15% from $686M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new ALLO positions and 21 closed out — a net gain of 9 holders — while 62 added to existing stakes and 48 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $24.4M. The largest seller was Millennium Management, cutting an estimated $14.6M.
- 176 institutional investors held Allogene Therapeutics (ALLO) as of Q1 2023, up from 167 in Q4 2022.
- Funds reported $582M of Allogene Therapeutics stock for Q1 2023, down 15% quarter-over-quarter.
- 30 funds opened new Allogene Therapeutics positions in Q1 2023 and 21 closed out, a net change of +9 holders.
- The largest Allogene Therapeutics buyer in Q1 2023 was Citadel Advisors, an estimated $24.4M added.
- The largest Allogene Therapeutics seller in Q1 2023 was Millennium Management, an estimated $14.6M sold.
Based on aggregated 13F filings for Q1 2023.